BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36550239)

  • 1. Molecular dynamics-based insight of VEGFR-2 kinase domain: a combined study of pharmacophore modeling and molecular docking and dynamics.
    Parves MR; Riza YM; Alam S; Jaman S
    J Mol Model; 2022 Dec; 29(1):17. PubMed ID: 36550239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
    Matore BW; Roy PP; Singh J
    J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
    Rampogu S; Baek A; Zeb A; Lee KW
    BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
    Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
    Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
    Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
    Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
    Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
    Molecules; 2023 May; 28(10):. PubMed ID: 37241785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
    Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
    J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of VEGFR inhibitors through virtual screening and energy assessment.
    Reang J; Sharma K; Sharma PC; Yadav V; Sharma V; Majeed J
    J Biochem Mol Toxicol; 2023 May; 37(5):e23321. PubMed ID: 36808794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
    Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
    J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.
    Rampogu S; Baek A; Park C; Parate S; Parameswaran S; Park Y; Shaik B; Kim JH; Park SJ; Lee KW
    Cells; 2019 Mar; 8(3):. PubMed ID: 30901950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies.
    Banerjee S; Kejriwal S; Ghosh B; Lanka G; Jha T; Adhikari N
    J Biomol Struct Dyn; 2024; 42(2):1047-1063. PubMed ID: 37029768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
    Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
    J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.